In patients with T2D and DKD, ADA and KDIGO recommend the addition of a GLP-1 receptor agonist in those unable to achieve individualized glycemic goals despite first-line treatment with an SGLT2 inhibitor and metformin [23]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.